GMP issues for recombinant plant-derived pharmaceutical proteinsFISCHER, Rainer; SCHILLBERG, Stefan; HELLWIG, Stephan et al.Biotechnology advances. 2012, Vol 30, Num 2, pp 434-439, issn 0734-9750, 6 p.Article

Production of biologically active recombinant human factor H in PhyscomitrellaBÜTTNER-MAINIK, Annette; PARSONS, Juliana; JEROME, Hanna et al.Plant biotechnology journal (Print). 2011, Vol 9, Num 3, pp 373-383, issn 1467-7644, 11 p.Article

Animal pharming, two decades onKIND, Alexander; SCHNIEKE, Angelika.Transgenic research. 2008, Vol 17, Num 6, pp 1025-1033, issn 0962-8819, 9 p.Article

Medium term planning of biopharmaceutical manufacture with uncertain fermentation titersLAKHDAR, Kais; FARID, Suzanne S; TITCHENER-HOOKER, Nigel J et al.Biotechnology progress. 2006, Vol 22, Num 6, pp 1630-1636, issn 8756-7938, 7 p.Article

Strategic Biopharmaceutical Portfolio Development : An Analysis of Constraint-Induced ImplicationsGEORGE, Edmund D; FARID, Suzanne S.Biotechnology progress. 2008, Vol 24, Num 3, pp 698-713, issn 8756-7938, 16 p.Conference Paper

Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin AmericaIBARRA-CABRERA, Ricardo; MENA-PEREZ, Sandra Carolina; BONDANI-GUASTI, Augusto et al.Biotechnology advances. 2013, Vol 31, Num 8, pp 1333-1343, issn 0734-9750, 11 p.Article

Estimating production technical efficiency for the US biopharmaceutical industryLIN, Yi-Hsing; HONG, Chun-Fu.International journal of biotechnology. 2012, Vol 12, Num 3, pp 184-197, issn 0963-6048, 14 p.Article

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 325-331, issn 0734-9750, 7 p.Article

Biomédicaments : des perspectives thérapeutiques prometteuses dans le traitement des formes modérées à sévères du psoriasis en plaquesMADIOU, Jean-Philippe.Images en dermatologie. 2012, Vol 5, issn 1964-4167, 17 p., SUPSerial Issue

A special report on India's biotech scenario: Advancement in biopharmaceutical and health care sectorsCHAKRABORTY, Chiranjib; AGORAMOORTHY, Govindasamy.Biotechnology advances. 2010, Vol 28, Num 1, pp 1-6, issn 0734-9750, 6 p.Article

Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification SystemRAMIREZ, Elena; LAOSA, Olga; GUERRA, Pedro et al.British journal of clinical pharmacology. 2010, Vol 70, Num 5, pp 694-702, issn 0306-5251, 9 p.Article

The production of biopharmaceuticals in plant systemsKARG, Saskia R; KALLIO, Pauli T.Biotechnology advances. 2009, Vol 27, Num 6, pp 879-894, issn 0734-9750, 16 p.Article

Immunogenicity of therapeutic proteins. Part 1: Impact of product handlingSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 310-317, issn 0734-9750, 8 p.Article

Mammalian cell protein expression for biopharmaceutical production : Production of Recombinant ProteinsJIANWEI ZHU.Biotechnology advances. 2012, Vol 30, Num 5, pp 1158-1170, issn 0734-9750, 13 p.Article

Multiobjective Long-Term Planning of Biopharmaceutical Manufacturing FacilitiesLAKHDAR, K; SAVERY, J; PAPAGEORGIOU, L. G et al.Biotechnology progress. 2007, Vol 23, Num 6, pp 1383-1393, issn 8756-7938, 11 p.Article

Phage passage after extended processing in small-virus-retentive filtersLUTE, Scott; BAILEY, Mark; COMBS, Jessica et al.Biotechnology and applied biochemistry. 2007, Vol 47, pp 141-151, issn 0885-4513, 11 p., 3-4Article

Defining viability in mammalian cell culturesBROWNE, Susan M; AL-RUBEAI, Mohamed.Biotechnology letters. 2011, Vol 33, Num 9, pp 1745-1749, issn 0141-5492, 5 p.Article

Approval of new biopharmaceuticals 1999-2006 : Comparison of the US, EU and Japan situationsTSUJI, Kaori; TSUTANI, Kiichiro.European journal of pharmaceutics and biopharmaceutics. 2008, Vol 68, Num 3, pp 496-502, issn 0939-6411, 7 p.Article

Towards industrial usefulness - cryo-cell-banking of transgenic BY-2 cell culturesSCHMALE, Kathrin; RADEMACHER, Thomas; FISCHER, Rainer et al.Journal of biotechnology. 2006, Vol 124, Num 1, pp 302-311, issn 0168-1656, 10 p.Article

The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugsJEFFERIS, Roy.Biotechnology & genetic engineering reviews. 2010, Vol 26, pp 1-41, issn 0264-8725, 41 p.Article

Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectivesROSALES-MENDOZA, Sergio; TERESITA PAZ-MALDONADO, Luz Maria; SORIA-GUERRA, Ruth Elena et al.Plant cell reports (Print). 2012, Vol 31, Num 3, pp 479-494, issn 0721-7714, 16 p.Article

Engineering of glycosylation in yeast and other fungi: current state and perspectivesDE POURCQ, Karen; DE SCHUTTER, Kristof; CALLEWAERT, Nico et al.Applied microbiology and biotechnology. 2010, Vol 87, Num 5, pp 1617-1631, issn 0175-7598, 15 p.Article

Using cell engineering and omic tools for the improvement of cell culture processesKUYSTERMANS, Darrin; KRAMPE, Britta; SWIDEREK, Halina et al.Cytotechnology (Dordrecht). 2007, Vol 53, Num 1-3, pp 3-22, issn 0920-9069, 20 p.Article

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticalsEBBERS, Hans C; MANTEL-TEEUWISSE, Aukje K; SAYED-TABATABAEI, Fakhredin A et al.European journal of clinical pharmacology. 2013, Vol 69, Num 2, pp 217-226, issn 0031-6970, 10 p.Article

Current achievements in the production of complex biopharmaceuticals with moss bioreactorsDECKER, Eva L; RESKI, Ralf.Bioprocess and biosystems engineering (Print). 2008, Vol 31, Num 1, pp 3-9, issn 1615-7591, 7 p.Article